Spero Therapeutics provides 2024 outlook; cash $76.3M, runway into late 2025; SPR720 Phase 2a data due 2H 2024

Spero Therapeutics, Inc.

Preliminary cash and cash equivalents of $76.3M as of Dec 31, 2023 (unaudited).
Cash plus $95M in GSK development milestones expected to fund operations into late 2025.
PIVOT-PO Phase 3 trial of tebipenem HBr for cUTI initiated; target enrollment ~2,648 patients; completion expected 2H 2025.
SPR720 Phase 2a topline data for NTM-PD expected in second half of 2024.
Company entitled to $95M in development milestones from GSK, payable in four equal installments over two years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.